Jelleine: Difference between revisions
Content deleted Content added
Citation bot (talk | contribs) Added pmc. | Use this bot. Report bugs. | Suggested by Abductive | Category:Articles needing expert attention from January 2024 | #UCB_Category 22/37 |
m Fixed typos |
||
| Line 10: | Line 10: | ||
== Discovery == |
== Discovery == |
||
Jelleines were first isolated in 2004 by the research group of Professor Mario Sergio Palma at [[São Paulo State University]], Brazil. First, he collected the royal jelly of a group of honey bee larvae and purified the results by reverse phase [[high-performance liquid chromatography]]. These |
Jelleines were first isolated in 2004 by the research group of Professor Mario Sergio Palma at [[São Paulo State University]], Brazil. First, he collected the royal jelly of a group of honey bee larvae and purified the results by reverse phase [[high-performance liquid chromatography]]. These pieces of royal jelly then showed antimicrobial activity against different bacteria.<ref name="auto">{{Cite journal |title=Jelleines: a family of antimicrobial peptides from the Royal Jelly of honeybees (Apis mellifera)|first1=Renato|last1=Fontana|first2=Maria Anita|last2=Mendes|first3=Bibiana Monson|last3=de Souza|first4=Katsuhiro|last4=Konno|first5=Lílian Mari Marcondes|last5=César|first6=Osmar|last6=Malaspina|first7=Mario Sergio|last7=Palma|date=June 26, 2004|journal=Peptides|volume=25|issue=6|pages=919–928|doi=10.1016/j.peptides.2004.03.016|pmid=15203237|s2cid=6839870 }}</ref> So far 4 peptides have been found in this family, each one containing the [[carboxamide|Carboxamide C-Terminal]]. |
||
== Health benefits == |
== Health benefits == |
||
Fungal spores lead to respiratory disease in more that 10 |
Fungal spores lead to respiratory disease in more that 10 million people.<ref>{{Cite journal|title=Fungal diseases as neglected pathogens: A wake-up call to public health officials|first1=Marcio L.|last1=Rodrigues|first2=Joshua D.|last2=Nosanchuk|date=February 26, 2020|journal=PLOS Neglected Tropical Diseases|volume=14|issue=2|pages=e0007964|doi=10.1371/journal.pntd.0007964|doi-access=free |pmid=32078635|pmc=7032689}}</ref> Compared to current antifungal agents, Jelleine has the potential to be a less toxic and overall improved agent. So far Jelleine-I has been shown to work against ''[[Candida albicans]]'',<ref name="auto"/> ''C. tropicalis'', ''C. parapsilosis'', and ''C. glabrata''.<ref>{{Cite journal|title=Development of a Novel Short Synthetic Antibacterial Peptide Derived from the Swallowtail Butterfly Papilio xuthus Larvae|first1=Seong Ryul|last1=Kim|first2=Kwang-Ho|last2=Choi|first3=Kee-Young|last3=Kim|first4=Hye-Yong|last4=Kwon|first5=Seung-Won|last5=Park|date=September 28, 2020|journal=Journal of Microbiology and Biotechnology|volume=30|issue=9|pages=1305–1309|doi=10.4014/jmb.2003.03009|pmid=32627752|pmc=9728235}}</ref> Jelleine-I causes damage that promotes microbial [[lysis]], in addition it has been shown to stimulate the formation of reactive oxygen species which improve its defence against ''Candida''. In a test Kunming mice were infected with ''C. Albicans'', one hour after infection they were given different doses of jelleine-I over a period of 7 days. at the end of the experiment. The antifungal effect of Jelleine-I kept 60% of its group alive, while a separate group given [[Fluconazole]] only kept 40% alive and the untreated control group had a 100% mortality rate.<ref>{{Cite journal|url=https://doi.org/10.1007/s00726-017-2507-1|title=The in vitro, in vivo antifungal activity and the action mode of Jelleine-I against Candida species|first1=Fengjing|last1=Jia|first2=Jiayi|last2=Wang|first3=Jinxiu|last3=Peng|first4=Ping|last4=Zhao|first5=Ziqing|last5=Kong|first6=Kairong|last6=Wang|first7=Wenjin|last7=Yan|first8=Rui|last8=Wang|date=February 1, 2018|journal=Amino Acids|volume=50|issue=2|pages=229–239|via=Springer Link|doi=10.1007/s00726-017-2507-1|pmid=29101485 |s2cid=254077869 }}</ref> |
||
Jelleine also has an antiparasitic ability against pathogens such as ''[[Leishmania]]''. Most drugs administered are both toxic and prone to side effects.<ref>{{Cite journal |last1=Ponte-Sucre |first1=Alicia |last2=Gamarro |first2=Francisco |last3=Dujardin |first3=Jean-Claude |last4=Barrett |first4=Michael P. |last5=López-Vélez |first5=Rogelio |last6=García-Hernández |first6=Raquel |last7=Pountain |first7=Andrew W. |last8=Mwenechanya |first8=Roy |last9=Papadopoulou |first9=Barbara |date=2017 |title=Drug resistance and treatment failure in leishmaniasis: A 21st century challenge |journal=Neglected Tropical Diseases |volume=11 |issue=12 |pages=e0006052 |doi=10.1371/journal.pntd.0006052 |doi-access=free |issn=1935-2735 |pmc=5730103 |pmid=29240765}}</ref> Jelleine-I has low anti-leishmania activity, being able to stop [[promastigote]]s but having no effect on the [[amastigote]]s.<ref>{{Cite journal |last1=Zahedifard |first1=Farnaz |last2=Lee |first2=Hyeryon |last3=No |first3=Joo Hwan |last4=Salimi |first4=Mona |last5=Seyed |first5=Negar |last6=Asoodeh |first6=Ahmad |last7=Rafati |first7=Sima |date=2020-02-01 |title=Comparative study of different forms of Jellein antimicrobial peptide on Leishmania parasite |url=https://www.sciencedirect.com/science/article/pii/S0014489419302814 |journal=Experimental Parasitology |volume=209 |pages=107823 |doi=10.1016/j.exppara.2019.107823 |pmid=31862270 |s2cid=209434945 |issn=0014-4894}}</ref> |
Jelleine also has an antiparasitic ability against pathogens such as ''[[Leishmania]]''. Most drugs administered are both toxic and prone to side effects.<ref>{{Cite journal |last1=Ponte-Sucre |first1=Alicia |last2=Gamarro |first2=Francisco |last3=Dujardin |first3=Jean-Claude |last4=Barrett |first4=Michael P. |last5=López-Vélez |first5=Rogelio |last6=García-Hernández |first6=Raquel |last7=Pountain |first7=Andrew W. |last8=Mwenechanya |first8=Roy |last9=Papadopoulou |first9=Barbara |date=2017 |title=Drug resistance and treatment failure in leishmaniasis: A 21st century challenge |journal=Neglected Tropical Diseases |volume=11 |issue=12 |pages=e0006052 |doi=10.1371/journal.pntd.0006052 |doi-access=free |issn=1935-2735 |pmc=5730103 |pmid=29240765}}</ref> Jelleine-I has low anti-leishmania activity, being able to stop [[promastigote]]s but having no effect on the [[amastigote]]s.<ref>{{Cite journal |last1=Zahedifard |first1=Farnaz |last2=Lee |first2=Hyeryon |last3=No |first3=Joo Hwan |last4=Salimi |first4=Mona |last5=Seyed |first5=Negar |last6=Asoodeh |first6=Ahmad |last7=Rafati |first7=Sima |date=2020-02-01 |title=Comparative study of different forms of Jellein antimicrobial peptide on Leishmania parasite |url=https://www.sciencedirect.com/science/article/pii/S0014489419302814 |journal=Experimental Parasitology |volume=209 |pages=107823 |doi=10.1016/j.exppara.2019.107823 |pmid=31862270 |s2cid=209434945 |issn=0014-4894}}</ref> |
||
Revision as of 17:30, 18 April 2024
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
Jelleine is a family of peptides isolated from the royal jelly of Apis mellifera iberiensis, a subspecies of honey bee. The new family has potential to be used in the development of new drugs.[1]
Discovery
Jelleines were first isolated in 2004 by the research group of Professor Mario Sergio Palma at São Paulo State University, Brazil. First, he collected the royal jelly of a group of honey bee larvae and purified the results by reverse phase high-performance liquid chromatography. These pieces of royal jelly then showed antimicrobial activity against different bacteria.[2] So far 4 peptides have been found in this family, each one containing the Carboxamide C-Terminal.
Health benefits
Fungal spores lead to respiratory disease in more that 10 million people.[3] Compared to current antifungal agents, Jelleine has the potential to be a less toxic and overall improved agent. So far Jelleine-I has been shown to work against Candida albicans,[2] C. tropicalis, C. parapsilosis, and C. glabrata.[4] Jelleine-I causes damage that promotes microbial lysis, in addition it has been shown to stimulate the formation of reactive oxygen species which improve its defence against Candida. In a test Kunming mice were infected with C. Albicans, one hour after infection they were given different doses of jelleine-I over a period of 7 days. at the end of the experiment. The antifungal effect of Jelleine-I kept 60% of its group alive, while a separate group given Fluconazole only kept 40% alive and the untreated control group had a 100% mortality rate.[5]
Jelleine also has an antiparasitic ability against pathogens such as Leishmania. Most drugs administered are both toxic and prone to side effects.[6] Jelleine-I has low anti-leishmania activity, being able to stop promastigotes but having no effect on the amastigotes.[7]
Jelleine-I and its halogenated analogues show potential to be used as an immunologic adjuvant in the treatment of colorectal cancer.[citation needed] These peptides inhibit Fusobacterium nucleatum, an anaerobic bacterium of the oral microbiota that is highly active in the altered microecology of the gut and is closely associated with the initiation and progression of CRC.[8]
References
- ^ Lima, William Gustavo; Brito, Julio Cesar Moreira; Verly, Rodrigo Moreira; Lima, Maria Elena de (January 26, 2024). "Jelleine, a Family of Peptides Isolated from the Royal Jelly of the Honey Bees (Apis mellifera), as a Promising Prototype for New Medicines: A Narrative Review". Toxins. 16 (1): 24. doi:10.3390/toxins16010024. PMC 10819630. PMID 38251241.
- ^ a b Fontana, Renato; Mendes, Maria Anita; de Souza, Bibiana Monson; Konno, Katsuhiro; César, Lílian Mari Marcondes; Malaspina, Osmar; Palma, Mario Sergio (June 26, 2004). "Jelleines: a family of antimicrobial peptides from the Royal Jelly of honeybees (Apis mellifera)". Peptides. 25 (6): 919–928. doi:10.1016/j.peptides.2004.03.016. PMID 15203237. S2CID 6839870.
- ^ Rodrigues, Marcio L.; Nosanchuk, Joshua D. (February 26, 2020). "Fungal diseases as neglected pathogens: A wake-up call to public health officials". PLOS Neglected Tropical Diseases. 14 (2): e0007964. doi:10.1371/journal.pntd.0007964. PMC 7032689. PMID 32078635.
- ^ Kim, Seong Ryul; Choi, Kwang-Ho; Kim, Kee-Young; Kwon, Hye-Yong; Park, Seung-Won (September 28, 2020). "Development of a Novel Short Synthetic Antibacterial Peptide Derived from the Swallowtail Butterfly Papilio xuthus Larvae". Journal of Microbiology and Biotechnology. 30 (9): 1305–1309. doi:10.4014/jmb.2003.03009. PMC 9728235. PMID 32627752.
- ^ Jia, Fengjing; Wang, Jiayi; Peng, Jinxiu; Zhao, Ping; Kong, Ziqing; Wang, Kairong; Yan, Wenjin; Wang, Rui (February 1, 2018). "The in vitro, in vivo antifungal activity and the action mode of Jelleine-I against Candida species". Amino Acids. 50 (2): 229–239. doi:10.1007/s00726-017-2507-1. PMID 29101485. S2CID 254077869 – via Springer Link.
- ^ Ponte-Sucre, Alicia; Gamarro, Francisco; Dujardin, Jean-Claude; Barrett, Michael P.; López-Vélez, Rogelio; García-Hernández, Raquel; Pountain, Andrew W.; Mwenechanya, Roy; Papadopoulou, Barbara (2017). "Drug resistance and treatment failure in leishmaniasis: A 21st century challenge". Neglected Tropical Diseases. 11 (12): e0006052. doi:10.1371/journal.pntd.0006052. ISSN 1935-2735. PMC 5730103. PMID 29240765.
- ^ Zahedifard, Farnaz; Lee, Hyeryon; No, Joo Hwan; Salimi, Mona; Seyed, Negar; Asoodeh, Ahmad; Rafati, Sima (2020-02-01). "Comparative study of different forms of Jellein antimicrobial peptide on Leishmania parasite". Experimental Parasitology. 209: 107823. doi:10.1016/j.exppara.2019.107823. ISSN 0014-4894. PMID 31862270. S2CID 209434945.
- ^ Jia, Fengjing; Yu, Qun; Wang, Ruolei; Zhao, Ling; Yuan, Fuwen; Guo, Haidong; Shen, Yunhui; He, Feng (2023-01-11). "Optimized Antimicrobial Peptide Jelleine-I Derivative Br-J-I Inhibits Fusobacterium Nucleatum to Suppress Colorectal Cancer Progression". International Journal of Molecular Sciences. 24 (2): 1469. doi:10.3390/ijms24021469. ISSN 1422-0067. PMC 9865857. PMID 36674985.
 | This article needs additional or more specific categories. (January 2024) |